Stockscreener 앱 받기
9.40
1.57%
-0.15
시간 외 거래:
9.36
-0.04
-0.43%
전일 마감가:
$9.55
열려 있는:
$9.48
하루 거래량:
644.99K
Relative Volume:
0.60
시가총액:
$551.89M
수익:
$106.47M
순이익/손실:
$82.89M
주가수익비율:
6.2935
EPS:
1.4936
순현금흐름:
$-2.43M
1주 성능:
-7.71%
1개월 성능:
+5.74%
6개월 성능:
+22.56%
1년 성능:
+18.24%
1일 변동 폭
$9.314
$9.55
1주일 범위
$9.314
$10.71
52주 변동 폭
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
명칭
Zevra Therapeutics Inc
전화
(888) 958-1253
주소
101 FEDERAL STREET, BOSTON
Compare ZVRA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
9.40 | 560.70M | 106.47M | 82.89M | -2.43M | 1.4936 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 개시 | BTIG Research | Buy |
| 2025-07-02 | 개시 | H.C. Wainwright | Buy |
| 2025-01-08 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-10-07 | 개시 | Guggenheim | Buy |
| 2024-09-24 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-24 | 재확인 | Maxim Group | Buy |
| 2024-04-02 | 재확인 | Maxim Group | Buy |
| 2024-03-12 | 개시 | William Blair | Outperform |
| 2023-03-17 | 개시 | Maxim Group | Buy |
모두보기
Zevra Therapeutics Inc 주식(ZVRA)의 최신 뉴스
CFO at Zevra (NASDAQ: ZVRA) receives 300,000-share option grant - Stock Titan
Zevra Therapeutics appoints Justin Renz as CFO - MSN
Nio, Zevra Therapeutics, Vertex Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook - Investing.com Nigeria
R. LaDuane Clifton (ZVRA) files Form 144 showing 11,000‑ and 3,000‑share sales - Stock Titan
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million and Settles Delaware Lawsuit 1 - Minichart
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap UpStill a Buy? - MarketBeat
Zevra Therapeutics Agrees to Sell SDX Portfolio to Commave Therapeutics for $50 Million - marketscreener.com
Zevra Shares Jump After Selling SDX Portfolio For $50M - Benzinga
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook By Investing.com - Investing.com Australia
Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by BTIG Research - MarketBeat
Zevra Therapeutics (ZVRA) Sells Serdexmethylphenidate Portfolio to Commave for $50 Million - GuruFocus
Zevra Sells SDX Portfolio and Resolves Litigation - TipRanks
Zevra Therapeutics, Inc. $ZVRA Shares Bought by Kingdon Capital Management L.L.C. - MarketBeat
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million - Quiver Quantitative
Zevra Therapeutics Sells Sdx Portfolio To Commave Therapeutics For $50 Million - TradingView
Zevra Sells SDX Portfolio to Commave for $50 Million, Ends Azstarys Pact and Repays Credit Facility - TradingView
ZVRA: BTIG Initiates Coverage with a "Buy" Rating and $23.00 PT - GuruFocus
Zevra (Nasdaq: ZVRA) sells SDX portfolio for $50M and repays $63M loan - Stock Titan
BTIG initiates coverage of Zevra Therapeutics (ZVRA) with buy recommendation - MSN
Zevra jumps 19% after Q4 EPS tops consensus estimates - MSN
A Look At Zevra Therapeutics (ZVRA) Valuation After Profitability And MIPLYFFA Commercial Progress - Sahm
Zevra Therapeutics (NASDAQ:ZVRA) Cut to "Hold" at Wall Street Zen - MarketBeat
Aug Macro: Is Zevra Therapeutics Inc backed by strong institutional buying2026 Key Highlights & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Zevra Therapeutics, Inc.Common Stock (NQ: ZVRA - The Chronicle-Journal
Trading Systems Reacting to (ZVRA) Volatility - Stock Traders Daily
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
Analysts Set Expectations for ZVRA Q1 Earnings - MarketBeat
ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
Zevra Therapeutics Faces Partnership Hurdles That Could Delay Drug Development and Pressure Financing - The Globe and Mail
Trading Action: Should I set a stop loss on Zevra Therapeutics IncEarnings Beat & Daily Profit Focused Screening - baoquankhu1.vn
Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price Performance - Yahoo Finance
WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C - Zacks Investment Research
Zevra at Citizens Life Sciences: Strategic Growth and Expansion By Investing.com - Investing.com Canada
Zevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
ZVRA: MIPLYFFA drives rare disease growth with strong revenue, global expansion, and pipeline progress - TradingView
Can Zevra Therapeutics (ZVRA) Turn NPC Genetic Testing Access Into a Durable Rare-Disease Edge? - Yahoo Finance
Zevra Therapeutics (ZVRA) Gets a Buy from Roth MKM - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Zevra Therapeutics (ZVRA) and Cooper Co (COO) - The Globe and Mail
Brokers Offer Predictions for ZVRA Q3 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Jazz Pharmaceuticals (JAZZ) and Talkspace (TALK) - The Globe and Mail
Zevra Therapeutics (ZVRA) Profit Swing To US$77.6m TTM Tests Rare Disease Bull Case - simplywall.st
Why Is Zevra Therapeutics Stock Trading Higher Today? - Bitget
Why Zevra Therapeutics stock zoomed 21% higher today - MSN
Why Zevra Therapeutics Stock Zoomed 21% Higher Today - Yahoo Finance
Zevra Therapeutics Appoints Justin Renz as New CFO - The Globe and Mail
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model (NASDAQ:ZVRA) - Seeking Alpha
GeneDx Holdings Corp. to Launch Genetic Testing Program with Zevra Therapeutics, Inc. to Support Patients with Suspected Niemann-Pick Disease Type C - marketscreener.com
Zevra Therapeutics Inc (ZVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Zevra Therapeutics Inc 주식 (ZVRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| McFarlane Neil F. | President and CEO |
Feb 09 '26 |
Sale |
8.56 |
14,625 |
125,186 |
387,225 |
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller |
Feb 03 '26 |
Sale |
9.18 |
3,000 |
27,548 |
29,590 |
| Schafer Joshua | CCO |
Feb 03 '26 |
Sale |
9.19 |
10,500 |
96,500 |
62,278 |
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller |
Jan 30 '26 |
Sale |
8.82 |
1,750 |
15,442 |
20,924 |
| Thompson Rahsaan | Chief Legal & Compliance |
Jan 30 '26 |
Sale |
8.83 |
4,080 |
36,010 |
49,919 |
| Quartel Adrian W | Chief Medical Officer |
Jan 30 '26 |
Sale |
8.83 |
4,533 |
40,036 |
9,723 |
| Schafer Joshua | CCO |
Jan 30 '26 |
Sale |
8.83 |
3,375 |
29,800 |
37,444 |
| McFarlane Neil F. | President and CEO |
Feb 02 '26 |
Sale |
9.38 |
91,000 |
853,425 |
364,350 |
1.20%
0.06%
자본화:
|
볼륨(24시간):